------------------------------------------------------------
[link removed]


** New Resources on AVAC.org
------------------------------------------------------------
May 21, 2020

Dear Advocate,

In this time of COVID-19, new information and new questions arise daily with implications for global health advocacy and for the HIV response at large. In the midst of this, HIV research has taken some major steps forward as well. AVAC has produced a number resources to keep you informed and guide your advocacy on all these issues.

In the Headlines: Research on long-acting PrEP for HIV prevention

AVAC’s Statement on HPTN 083 ([link removed]) —HPTN 083 stopped the placebo arm of this trial two years early, after a rescheduled review of the data showed the product was at least as good as oral PrEP. AVAC’s statement explains the trial, the findings and talks about what’s next. For a deeper dive into the trial design check out our infographic ([link removed]) or the Px Pulse episode on the issue ([link removed]) . You can also join an HPTN webinar on the results tomorrow, May 22nd, at 10:30am ET ([link removed]) .

COVID-19: Research standing on the shoulders of HIV
* AVAC’s new report, Five “P”s to Watch: Platforms, process, partnerships, payers and participatory practices that drive vaccine development ([link removed]) , connects the key issues and lays out how HIV vaccine research is making the search for a COVID-19 vaccine faster, smarter and more inclusive.
* Read HIV Advocates Respond to the COVID-19 Crises ([link removed]) , a blog by AVACer Daisy Ouya ([link removed]) looking at how advocates in the USAID-supported Coalition to Accelerate and Support Prevention Research (CASPR) ([link removed]) have adapted skills, resources and networks to empower communities and ease collective suffering.
* Our webinar, The Power–and Pitfalls–of Modeling for COVID-19 and HIV ([link removed]) , discusses current COVID-19 models and the benefits and limitations of mathematical models as they apply to both COVID-19 and HIV prevention.
* Listen to a webinar ([link removed]) on the COVID-19 vaccine pipeline with Science Magazine’s Jon Cohen ([link removed]) . Cohen talks about the rapidly growing pipeline, the direct links to HIV research and the risks of benefits of speeding up the process, including the thorny issue of human challenge trials. While the WHO issued criteria for assessing a challenge study ([link removed]) , AVAC and TAG ([link removed]) issued a joint statement ([link removed]) outlining concerns and necessary prerequesites to consider going forward this way.
* In case you missed it, the latest episode of Px Pulse features ([link removed]) a detailed look at the partnerships and innovation that can propel ethical research on HIV and COVID-19, and a status report on how ongoing HIV prevention trials are adapting during the COVID-19 pandemic.


Expanding Our Work: Integrating HIV prevention with sexual and reproductive health

AVAC has long promoted a research agenda centered on women, but both the ECHO trial results ([link removed]) and the rollout of PrEP have highlighted the urgent need to bring proven interventions for both HIV and sexual and reproductive health to the women who need them. In our blog Programs, Products, Services and Users: HIV & SRH integration is the future of prevention ([link removed]) we outline our expanding advocacy to advance HIV/SRH integration, introduce a suite of new resources ([link removed]) and our new page on avac.org devoted to HIV/SRH integration ([link removed]) .

Best,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])